Asthma is one of the most common chronic illnesses and it disproportionately affects disadvantaged populations residing in urban areas. Mouse allergen exposure, in particular, appears to play a critical role in the urban asthma epidemic for several reasons: (1) Mus m 1, the major mouse allergen, is found in 95% of inner-city homes, and is found in 100-fold higher concentrations in inner-city homes than in suburban homes;(2) As many as 25-50% of children with asthma living in urban areas have evidence of IgE-sensitization to mouse, making them susceptible to mouse allergen-triggered asthma symptoms;and (3) Home mouse allergen exposure is associated with more symptoms days, more rescue medication use, and more asthma related health care use among IgE-sensitized children with asthma. Although these are compelling observations, demonstrating that a reduction of mouse allergen exposure results in Improved asthma health in mouse-sensitized children with asthma is critical for establishing a causal role for mouse allergen exposure. Preliminary evidence indicating that a mouse allergen-targeted environmental intervention (MA-EI) is efficacious in reducing settled dust Mus m 1 levels by >75% provides the final piece of background data to support the hypothesis that a MA-EI will reduce asthma morbidity in mouse-sensitized individuals with asthma. To test this hypothesis, we propose conducting a multi-center, randomized clinical trial of MA-EI at two major Northeastern US urban centers with high prevalence of asthma and mouse sensitization and high home Mus m 1 levels.
Aim 1 is: To determine the efficacy of this MA-IE to: (a) Reduce asthma symptoms and rescue medication use, (b) Reduce asthma-related health care utilization, and (c) Improve physiologic and inflammatory markers of asthma disease activity among mouse-sensitized children with asthma.
Aim 2 is: To evaluate mouse-specific IgG and IgE as biomarkers of allergen exposure and asthma clinical status. The findings from the clinical trial will lend critical insight into the impact of home mouse allergen exposure on urban populations with asthma, and directly inform public health strategies to reduce the inner-city asthma burden.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI083238-04
Application #
8457108
Study Section
Special Emphasis Panel (ZAI1-KS-I (J1))
Program Officer
Dong, Gang
Project Start
2010-05-15
Project End
2015-04-30
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
4
Fiscal Year
2013
Total Cost
$1,526,185
Indirect Cost
$517,670
Name
Johns Hopkins University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Matsui, E C (2014) Environmental exposures and asthma morbidity in children living in urban neighborhoods. Allergy 69:553-8
Hackstadt, Amber J; Matsui, Elizabeth C; Williams, D'Ann L et al. (2014) Inference for environmental intervention studies using principal stratification. Stat Med 33:4919-33
Little, Frédéric F; Delgado, Diana M; Wexler, Philip J et al. (2014) Salivary inflammatory mediator profiling and correlation to clinical disease markers in asthma. PLoS One 9:e84449
Ahluwalia, Sharon K; Peng, Roger D; Breysse, Patrick N et al. (2013) Mouse allergen is the major allergen of public health relevance in Baltimore City. J Allergy Clin Immunol 132:830-5.e1-2
Matsui, Elizabeth C (2013) Management of rodent exposure and allergy in the pediatric population. Curr Allergy Asthma Rep 13:681-6
McCormack, Meredith C; Aloe, Charles; Curtin-Brosnan, Jean et al. (2013) Guideline-recommended fractional exhaled nitric oxide is a poor predictor of health-care use among inner-city children and adolescents receiving usual asthma care. Chest 144:923-9
Matsui, Elizabeth C (2013) Environmental control for asthma: recent evidence. Curr Opin Allergy Clin Immunol 13:417-25